VEA
MIRM icon

Virtus ETF Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History

Virtus ETF Advisers’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$370K Hold
4,000
– – 0.17% 152
2025
Q4 		$316K Hold
4,000
– – 0.15% 162
2025
Q3 		$293K Buy
+4,000
New +$254K 0.16% 167
2025
Q1 		– Sell
-8,270
Closed -$342K – 640
2024
Q4 		$342K Sell
8,270
-4,074
-33% -$170K 0.14% 211
2024
Q3 		$481K Hold
12,344
– – 0.23% 183
2024
Q2 		$422K Buy
12,344
+1,329
+12% +$34.8K 0.21% 183
2024
Q1 		$277K Buy
11,015
+1,585
+17% +$43.6K 0.15% 229
2023
Q4 		$278K Sell
9,430
-1,309
-12% -$39.6K 0.18% 229
2023
Q3 		$339K Sell
10,739
-1,390
-11% -$38.1K 0.21% 193
2023
Q2 		$314K Sell
12,129
-4,960
-29% -$132K 0.19% 193
2023
Q1 		$410K Buy
17,089
+299
+2% +$6.82K 0.23% 145
2022
Q4 		$327K Buy
16,790
+4,472
+36% +$88.4K 0.17% 235
2022
Q3 		$259K Buy
12,318
+181
+1% +$4.36K 0.1% 286
2022
Q2 		$236K Buy
12,137
+976
+9% +$23K 0.09% 308
2022
Q1 		$246K Sell
11,161
-656
-6% -$13.4K 0.11% 186
2021
Q4 		$188K Sell
11,817
-167
-1% -$2.6K 0.07% 234
2021
Q3 		$239K Sell
11,984
-618
-5% -$10.1K 0.11% 224
2021
Q2 		$218K Buy
12,602
+87
+0.7% +$1.56K 0.09% 284
2021
Q1 		$248K Buy
12,515
+223
+2% +$4.27K 0.1% 290
2020
Q4 		$215K Sell
12,292
-5,166
-30% -$102K 0.09% 338
2020
Q3 		$336K Sell
17,458
-2,377
-12% -$51K 0.18% 200
2020
Q2 		$386K Buy
+19,835
New +$331K 0.18% 214

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Virtus ETF Advisers's MIRM Position: Q1 2026 in Review

Virtus ETF Advisers held its Mirum Pharmaceuticals (MIRM) position steady in Q1 2026 at 4,000 shares worth $370K. The position accounts for 0.17% of the portfolio, ranked #152.

Virtus ETF Advisers first reported a position in MIRM in Q2 2020 and has held it in 22 quarters since. The position peaked at $481K in Q3 2024. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Virtus ETF Advisers held 4,000 shares of Mirum Pharmaceuticals worth $370K as of Q1 2026.
  • Virtus ETF Advisers left its Mirum Pharmaceuticals share count unchanged in Q1 2026.
  • Mirum Pharmaceuticals made up 0.17% of Virtus ETF Advisers's portfolio in Q1 2026, its #152 holding.
  • Virtus ETF Advisers first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Virtus ETF Advisers's Mirum Pharmaceuticals position peaked at $481K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.